Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children.
Capeding MR, Teshome S, Saluja T, Syed KA, Kim DR, Park JY, Yang JS, Kim YH, Park J, Jo SK, Chon Y, Kothari S, Yang SY, Ham DS, Ryu JH, Hwang HS, Mun JH, Lynch JA, Kim JH, Kim H, Excler JL, Sahastrabuddhe S. Capeding MR, et al. Among authors: saluja t. Vaccine. 2018 Jun 18;36(26):3794-3801. doi: 10.1016/j.vaccine.2018.05.038. Vaccine. 2018. PMID: 29776750 Free PMC article. Clinical Trial.
Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants.
Dhingra MS, Kundu R, Gupta M, Kanungo S, Ganguly N, Singh MP, Bhattacharya MK, Ghosh R, Kumar R, Sur D, Chadha SM, Saluja T. Dhingra MS, et al. Among authors: saluja t. Vaccine. 2014 Aug 11;32 Suppl 1:A117-23. doi: 10.1016/j.vaccine.2014.03.069. Vaccine. 2014. PMID: 25091664 Free article. Clinical Trial.
Live attenuated tetravalent (G1-G4) bovine-human reassortant rotavirus vaccine (BRV-TV): Randomized, controlled phase III study in Indian infants.
Saluja T, Palkar S, Misra P, Gupta M, Venugopal P, Sood AK, Dhati RM, Shetty A, Dhaded SM, Agarkhedkar S, Choudhury A, Kumar R, Balasubramanian S, Babji S, Adhikary L, Dupuy M, Chadha SM, Desai F, Kukian D, Patnaik BN, Dhingra MS. Saluja T, et al. Vaccine. 2017 Jun 16;35(28):3575-3581. doi: 10.1016/j.vaccine.2017.05.019. Epub 2017 May 20. Vaccine. 2017. PMID: 28536027 Clinical Trial.
The Dengue virus in Nepal: gaps in diagnosis and surveillance.
Gupta BP, Haselbeck A, Kim JH, Marks F, Saluja T. Gupta BP, et al. Among authors: saluja t. Ann Clin Microbiol Antimicrob. 2018 Jul 16;17(1):32. doi: 10.1186/s12941-018-0284-7. Ann Clin Microbiol Antimicrob. 2018. PMID: 30008269 Free PMC article. Review.
Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
Raghava Mohan V, Raj S, Dhingra MS, Aloysia D'Cor N, Singh AP, Saluja T, Kim DR, Midde VJ, Kim Y, Vemula S, Narla SK, Sah B, Ali M. Raghava Mohan V, et al. Among authors: saluja t. PLoS One. 2019 Jun 18;14(6):e0218033. doi: 10.1371/journal.pone.0218033. eCollection 2019. PLoS One. 2019. PMID: 31211792 Free PMC article. Clinical Trial.
Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report.
Capeding MR, Alberto E, Sil A, Saluja T, Teshome S, Kim DR, Park JY, Yang JS, Chinaworapong S, Park J, Jo SK, Chon Y, Yang SY, Ham DS, Ryu JH, Lynch J, Kim JH, Kim H, Excler JL, Wartel TA, Sahastrabuddhe S. Capeding MR, et al. Among authors: saluja t. Vaccine. 2020 Jun 9;38(28):4476-4483. doi: 10.1016/j.vaccine.2019.09.074. Epub 2019 Oct 1. Vaccine. 2020. PMID: 31585725 Free PMC article. Clinical Trial.
Review on the Recent Advances on Typhoid Vaccine Development and Challenges Ahead.
Syed KA, Saluja T, Cho H, Hsiao A, Shaikh H, Wartel TA, Mogasale V, Lynch J, Kim JH, Excler JL, Sahastrabuddhe S. Syed KA, et al. Among authors: saluja t. Clin Infect Dis. 2020 Jul 29;71(Suppl 2):S141-S150. doi: 10.1093/cid/ciaa504. Clin Infect Dis. 2020. PMID: 32725225 Free PMC article. Review.
Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study.
Capeding MR, Sil A, Tadesse BT, Saluja T, Teshome S, Alberto E, Kim DR, Park EL, Park JY, Yang JS, Chinaworapong S, Park J, Jo SK, Chon Y, Yang SY, Ryu JH, Cheong I, Shim KY, Lee Y, Kim H, Lynch JA, Kim JH, Excler JL, Wartel TA, Sahastrabuddhe S. Capeding MR, et al. Among authors: saluja t. EClinicalMedicine. 2020 Sep 9;27:100540. doi: 10.1016/j.eclinm.2020.100540. eCollection 2020 Oct. EClinicalMedicine. 2020. PMID: 33150320 Free PMC article.
94 results